标题
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
作者
关键词
COVID-19 vaccines, COVID-19, SARS-CoV-2, Neoplasms, Immunity, Seroconversion
出版物
EUROPEAN JOURNAL OF CANCER
Volume 159, Issue -, Pages 259-274
出版商
Elsevier BV
发表日期
2021-10-26
DOI
10.1016/j.ejca.2021.10.013
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Commentary: SARS-CoV-2 vaccines and cancer patients
- (2021) C. Corti et al. ANNALS OF ONCOLOGY
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
- (2021) Akshay Sharma et al. Lancet Haematology
- The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
- (2021) M.C. Garassino et al. ANNALS OF ONCOLOGY
- Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action
- (2021) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: recommendations from the French society for Immuno-Therapy of Cancer (FITC)
- (2021) Marie-Léa Gauci et al. EUROPEAN JOURNAL OF CANCER
- Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
- (2021) J. Barrière et al. ANNALS OF ONCOLOGY
- Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
- (2021) J. Barrière et al. ANNALS OF ONCOLOGY
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
- (2021) Logan Good et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
- (2021) Fulvia Pimpinelli et al. Journal of Hematology & Oncology
- Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
- (2021) Barliz Waissengrin et al. LANCET ONCOLOGY
- COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
- (2021) Aakash Desai et al. Nature Reviews Clinical Oncology
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- (2021) Astha Thakkar et al. CANCER CELL
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
- (2021) Oliver Van Oekelen et al. CANCER CELL
- Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer
- (2021) Jérôme Barrière et al. EUROPEAN JOURNAL OF CANCER
- Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study
- (2021) David J. Pinato et al. EUROPEAN JOURNAL OF CANCER
- The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience
- (2021) Gabriel Revon-Riviere et al. EUROPEAN JOURNAL OF CANCER
- High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
- (2021) Dominic Fong et al. EUROPEAN JOURNAL OF CANCER
- Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
- (2021) Patrick Harrington et al. LEUKEMIA
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
- (2021) Kazimieras Maneikis et al. Lancet Haematology
- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
- (2021) Daryl Geers et al. Science Immunology
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
- (2020) Wenhua Liang et al. LANCET ONCOLOGY
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Treating Leukemia in the Time of COVID-19
- (2020) Shilpa Paul et al. ACTA HAEMATOLOGICA
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.
- (2020) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte)
- (2020) Elise A. Chong et al. CLINICAL CANCER RESEARCH
- Cell-Mediated Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors
- (2020) Chang Kyung Kang et al. JOURNAL OF INFECTIOUS DISEASES
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience
- (2020) Anthony R. Mato et al. BLOOD
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- (2020) Lydia Scarfò et al. LEUKEMIA
- Determinants of COVID-19 disease severity in patients with cancer
- (2020) Elizabeth V. Robilotti et al. NATURE MEDICINE
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- (2020) Francesco Passamonti et al. Lancet Haematology
- Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease
- (2020) Thomas Hueso et al. BLOOD
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies
- (2020) Aakash Desai et al. CANCER
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
- (2020) Antoni Ribas et al. Cancer Discovery
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- (2019) Christine Ménétrier-Caux et al. Journal for ImmunoTherapy of Cancer
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
- (2019) Kristine A. Frerichs et al. HAEMATOLOGICA
- Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada
- (2019) Phillip S. Blanchette et al. JOURNAL OF CLINICAL ONCOLOGY
- The response to vaccination against influenza A(H1N1) 2009, seasonal influenza andStreptococcus pneumoniaein adult outpatients with ongoing treatment for cancer with and without rituximab
- (2014) Åke Berglund et al. ACTA ONCOLOGICA
- Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2014) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started